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Background: 5-Fluorouracil (5-FU) is the cornerstone of chemotherapeutic treatment for patients with colorectal
cancer. The enzyme thymidine phosphorylase (TP) catalyzes the conversion of 5-FU to its active metabolite,
5-fluoro-2’-deoxyuridine. TP is expressed in tumour epithelial cells and stromal cells, particularly in tumour-associated
macrophages. These macrophages may affect sensitivity to chemotherapy. Previously, we identified TP as a
predictive factor in microdissected tumour samples of patients with advanced colorectal cancer. In the present
study, we analysed TP expression in tissues and associated stromal cells from patients with advanced colorectal
cancer and associated TP levels to tumour response and time-to-event variables during first-line chemotherapy
treatment. We also investigated the association between serum TP levels at the time of surgery and gene
expression in primary tumour tissues.
Methods: This study included 125 patients with metastatic colorectal cancer treated with first-line 5-FU-based
chemotherapy. To quantify TP gene expression levels in tumour tissues, real-time polymerase chain reaction was
performed using the 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA). TP protein
concentration in matched serum samples was determined using an enzyme-linked immunosorbent assay system
(USCN Life Science Inc.).
Results: The tumour response rate was 31%, and 30% of patients exhibited stable disease. No associations
between TP expression level and age or gender were observed. Levels of TP mRNA in mucosa and tumours were
positively correlated (r = 0.41, p < 0.01). No correlation between TP expression and tumour response rate was
observed. Time to progression was significantly longer in patients with high TP expression (p < 0.01). Serum TP
protein levels were not associated with tumour response or time-to-event variables and did not correlate with
gene expression in tumour tissues.
Conclusions: High TP gene expression in non-microdissected tumour tissues of patients with advanced colorectal
cancer correlates with longer time to progression, which could be related to treatment. These results are in
contrast to previous studies where microdissected tumour cells were analysed and may be due to the presence of
adjacent stromal cells. Serum TP protein expression does not correlate to TP gene expression in tissues of patients
with advanced colorectal cancer.
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Table 1 Primer and probe sequences used in the
real-time quantitative polymerase chain reaction
TP Probe 5′-CAG CCA GAG ATG TGA CAG CCA
CCG T-3′
forward primer 5′-CCT GCG GAC GGA ATC CTA TA-3′
reverse primer 5′-TGT GAT GAG TGG CAG GCT GT-3′
β-actin probe 5′-CCT GAA CCC CAA GGC CAA CCG-3′
forward primer 5′-CGT GCT GCT GAC CGA GG-3′
reverse primer 5′-GAA GGT CTC AAA CAT GAT CTG GGT-3′
Abbreviations: TP Thymidine Phosphorylase.
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To date, 5-fluorouracil (5-FU) constitutes the fundamen-
tal basis of chemotherapy treatment for patients with
colorectal cancer. The enzyme thymidine phosphorylase
(TP; E.C. 2.4.2.4) catalyzes the conversion of 5-FU to its
more active nucleoside form, 5-fluoro-2’-deoxyuridine,
representing one of the main pathways by which this
drug exerts its cytotoxic effect [1]. In the cell, TP is in-
volved in pyrimidine metabolism. Previous studies have
shown that TP levels are higher in tumour compared with
normal tissues in a wide range of solid tumours [2-5]. TP
and its catalytic product, 2-deoxy-D-ribose-1-phosphate
act as angiogenic factors via induction of endothelial cell
migration and tube formation [6-9]. In hypoxic environ-
ments, TP may also impart resistance to apoptosis [1,10].
TP expression is observed in tumour epithelial cells and
stromal cells, particularly in tumour-associated macro-
phages (TAMs) [4,8,11].
Previously, we identified TP gene expression in mi-
crodissected tumour samples from colorectal carcin-
omas as a possible predictor of chemotherapy response
and survival in advanced colorectal cancer [12]. This
finding was in keeping with the observations of other
independent reports [12-15]. In the present study, we
included tumour-associated stromal cells in our ana-
lysis of TP gene expression, because the majority of ex-
pression appears to be associated with TAMs. These
specific macrophages play an important role in the
tumour microenvironment and may affect sensitivity
to chemotherapy [16].
Previous studies have shown that plasma TP is elevated
in cancer patients [17,18]. Furthermore, high serum TP
(sTP) in patients with oesophageal and uterine cervical
cancer appears to be related to poor prognosis and inferior
response to chemotherapy [18,19]. In patients with colo-
rectal cancer, high levels of sTP in venous blood drainage
specimens were positively correlated with tumour stage,
poor prognosis and particularly, with risk of liver metas-
tasis [20]. However, to the best of our knowledge, no
studies investigating TP levels in peripheral blood sam-
ples of colorectal cancer patients have been conducted.
The primary aim of this study was to investigate the re-
lationship between tissue levels of TP in patients with
advanced colorectal cancer and tumour response and
time-to-event variables during first-line chemotherapy
treatment. Our second aim was to examine whether TP
gene expression in tumour tissues reflects TP protein
expression in serum samples at the time of surgery.
Methods
Patients and study design
This retrospective study included 125 patients with meta-
static colorectal cancer, treated with first line 5-FU-based
chemotherapy. Forty-one patients had previously receivedadjuvant chemotherapy. Fifty-six patients had rectal can-
cer and 61% of them received pre-operative irradiation.
All patients were treated at Sahlgrenska University
Hospital (Östra, Gothenburg, Sweden) between 2002
and 2011, and patients were followed up with CT scans
every 3 months during treatment. Treatment response
was evaluated according to criteria outlined by the
World Health Organization [21]. As first-line chemo-
therapy, 111 patients were treated according to the
Nordic FLV-protocol (500 mg/m2 of 5-FU in combin-
ation with 60 mg/m2 of leucovorin, given as a single
treatment (n = 31) or in combination with 85 mg/m2
oxaliplatin (n = 53) or 180 mg/m2 irinotecan (n = 27).
Fourteen patients received the 5-FU pro-drug capecita-
bine as a single treatment (n = 4), or in combination
with oxaliplatin (n = 3) or irinotecan (n = 7). First-line
therapy was continued until evidence of disease pro-
gression occurred, unacceptable toxicity developed, or
the patient elected to withdraw. Palliative survival was
defined as the time from first-line treatment until the
date of death. Ninety-nine patients died during the
follow-up period, while 26 remained alive [these patients
were censored in the survival analysis, with a median
follow-up time of 871 days (range 331–2766)]. Radiological
time to tumour progression was defined as the time
from initiation of first-line treatment to tumour progres-
sion, and 40 patients were censored for time to progres-
sion data. This study was approved by the Regional Ethical
Review Board in Gothenburg (EPN, Ö445-00).
Tissue and serum sampling
Tumour samples (n = 125) and matched macroscopically
normal-appearing mucosa (obtained approximately 10 cm
from the tumour, n = 125) were obtained from patients at
the time of primary surgery, snap-frozen in liquid nitrogen
and stored at −80°C until analysis. Matched venous blood
samples, which were collected pre-operatively in a stan-
dardized manner, were available from 70 of the 125 pa-
tients. For serum sampling, one tube without anticoagulant
was left at 20°C for 30 min. Samples were centrifuged for
10 min at 1519 × g and serum was gently collected and
frozen in small aliquots for downstream assays.
Table 2 Patient and tumour characteristics subgrouped according to high or low thymidine phosphorylase expression
Patient cohort Patient subgroup for serum analysis*
(n = 125) (n = 70)
tTP high tTP low sTP high sTP low
Age (year)
Median (IQR) 68 (59–75) 64 (57–73) 66 (56–75) 65 (59–74)
Gender (%)
Female 27 (44) 31 (49) 15 (43) 12 (34)
Male 35 (56) 32 (51) 20 (57) 23 (66)
Tumour location (%)
Colon 26 (42) 43 (68) 21 (60) 18 (51)
Rectum 36 (58) 20 (32) 14 (40) 17 (49)
Tumour stage (%)
I 4 (6) - 1 (3) -
II 17 (27) 4 (6) 6 (17) 6 (17)
III 24 (39) 27 (43) 12 (34) 16 (46)
IV 17 (27) 32 (51) 16 (46) 13 (37)
Tumour differentiation (%)
Well 1 (2) 1 (2) - 1 (3)
Medium 42 (68) 36 (57) 23 (66) 23 (66)
Poor 16 (26) 20 (32) 9 (26) 8 (23)
Mucinous 2 (3) 6 (10) 3 (9) 3 (8)
Unknown 1 (2) - - -
Assessed lymph nodes, median (IQR) 17 (12–24) 19 (16–25) 17 (14–26) 21 (14–29)
Positive lymph nodes, median (IQR) 1 (0–6) 4 (2–8) 3 (0–8) 3 (1–9)
T-stage (%)
1 - - - -
2 8 (13) - 2 (6) 2 (6)
3 36 (58) 32 (51) 16 (46) 19 (54)
4 13 (21) 25 (40) 15 (43) 14 (40)
Not evaluable 5 (8) 6 (10) 2 (6) -
N-stage (%)†‡
0 25 (40) 6 (10) 9 (26) 8 (23)
1a 8 (13) 9 (14) 6 (17) 5 (14)
1b 6 (10) 11 (17) 2 (6) 5 (14)
2a 9 (14) 15 (24) 7 (20) 5 (14)
2b 13 (21) 22 (35) 10 (28) 12 (34)
X 1 (2) - 1 (3) -
Metastatic sites (%)
Liver 24 (39) 27 (43) 13 (37) 19 (549
Pulmonary 3 (5) 3 (5) 1 (3) 2 (6)
Skeletal - 1 (2) - -
Local 3 (5) 2 (3) 3 (9) -
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Table 2 Patient and tumour characteristics subgrouped according to high or low thymidine phosphorylase expression
(Continued)
Multiple including liver 19 (31) 17 (27) 13 (37) 5 (14)
Multiple excluding liver 8 (13) 10 (16) 4 (11) 4 (11)
Lymphatic 5 (8) 3 (5) 1 (3) 5 (14)
Sum of percentages may not add up to 100 due to rounding.
Abbreviations: tTP tumour thymidine phosphorylase, sTP serum thymidine phosphorylase, IQR interquartile range.
*Serum was obtained from 70 patients.
†TNM, 7th edition from UICC/AJCC (Union for International Cancer Control/American Joint Committee on Cancer).
‡Data missing on one patient due to palliative surgery.
Lindskog et al. BMC Clinical Pathology 2014, 14:25 Page 4 of 7
http://www.biomedcentral.com/1472-6890/14/25Total RNA extraction, cDNA preparation and real-time
quantitative polymerase chain reaction (PCR)
Total RNA was isolated from 10 to 30 mg tissue using
the High Pure RNA Tissue Kit (Roche Diagnostics
GmbH). cDNA was synthesized using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). Real-time quantitative PCR was
performed using the 7500 Fast Real-Time PCR system
(Applied Biosystems). TP transcript levels were quanti-
fied using Assays-on-Demand™ from Applied Biosystems
(Hs00157317_m1). β-actin was used as an endogenous
control to normalize for RNA levels and efficiency of
the reverse-transcription reaction. Primer and probe se-
quences (Table 1) and multiplex PCR conditions were
previously described [22].
Enzyme-linked immunosorbent assay (ELISA)
The concentration of TP protein in patient serum samples
(sTP) was determined using a commercially available
ELISA system (E90948Hu; USCN Life Science Inc.,
Wuhan, China) according to manufacturer’s instructions
for quantitative measurements. The minimum detection
limit was < 0.25 ng/mL and the intra- vs inter-assay vari-
ation (CV%) was < 10% and 12%, respectively, as stated by
the manufacturer. Absorbance was measured at 450 nm
using a plate reader and serum protein concentration was
calculated using associated software (V-max/Softmax Pro;
Molecular Devices, USA). Results were normalized to total
protein content using a 96-well based assay method from
Bio-Rad (Hercules, CA, USA) according to the method
described by Lowry et al. [23].
Statistical methods
Data were analysed by statistical modelling using JMP
commercial software (version 10; SAS Inc., Cary, NC,
USA). Differences between groups were calculated using
the Kruskal–Wallis’ test or the Pearson’s Chi-square test.
The Pearson correlation coefficient (r) was used to com-
pare sets of continuous parameters measured in the same
tissue. The relative real-time quantitative PCR values and
protein levels of TP were dichotomized for subsequent
time-to-event analysis with respect to the median value of
expression. Tumours with gene expression levels lower orhigher than the median value were classified as low or
high expression status, respectively. Survival and time-
to-event curves were calculated by the Kaplan–Meier
method and statistically significant differences in survival
were calculated using the log-rank test. Relative risk was
assessed by uni- and multivariate Cox proportional hazard
model. Statistical values of p ≤ 0.05 were considered
significant.Results
Relative TP gene expression
Patient and tumour characteristics are presented in
Table 2. The median age of all patients (n = 125) was
65 years and 46% of patients were female. There was no
association between relative tumour TP (tTP) gene ex-
pression and age or gender. The expression of tTP was
associated with tumour location, with rectal carcinomas
exhibiting higher median tTP expression compared with
colon carcinomas (0.32, IQR 0.10–0.57 and 0.15, IQR
0.060–0.37, respectively, p < 0.01). This difference in TP
gene expression was not observed in mucosa samples.
We also observed a positive correlation between tTP and
mucosa TP (mTP, r = 0.41, p < 0.01).
The total tumour response rate was 31% (complete
response 4%, partial response 27%) and 30% of patients
exhibited stable disease. Patients were grouped accord-
ing to high/low tTP gene expression using a median
value cut-off (0.20, IQR 0.080–0.51). While no rela-
tionship between tumour response during treatment
and tTP expression was observed, we noted that time
to progression was extended in the high tTP expression
group (p < 0.01, Figure 1). Cox multivariate analysis
showed that tTP gene expression was significantly as-
sociated with time to progression (Table 3), and inde-
pendent of other parameters included in the model.
No correlation between tTP expression and palliative
survival was observed. All patients with stage I disease
(4/4) and two-thirds of patients with stage II disease
(14/21) were in the high tTP expression group. There
was no association between mTP gene expression (me-
dian value 0.29, IQR 0.19–0.44) and tumour response
or time-to-event variables.
Figure 1 Patients with high thymidine phosphorylase (TP) gene
expression (n = 62, dotted line) in tumour tissues exhibited
significantly longer time to progression compared with
patients with low expression (n = 63, solid line).
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TP protein levels were analysed in serum samples of 70
patients. Patient demographic information and tumour
characteristics of these patients were similar to those de-
scribed for the whole study population (Table 2). ThereTable 3 Cox univariate and multivariate analyses demonstrat
TP gene expression on time to progression
Univariate
HR 95% CI P
Gender
Male 1
Female 1.46 0.95-2.25 N
Age (years) 1.00 0.99-1.03 N
Tumour location
Rectum 1




Mucinous 2.04 0.84-4.23 N
TP gene expression
High 1




2-3 6.51 2.44-14.5 <
Chemotherapy
Combination treatment† 1
Single treatment‡ 1.29 0.78-2.07 N
Abbreviation: HR Hazard Ratio, CI Confidence interval, TP Thymidine Phosphorylase,
proportional hazards regression. †5-fluorouracil or capecitabine in combination withwas no correlation between sTP levels, age, gender or
tumour location. No significant correlation between
sTP at the time of surgery and tTP or mTP was ob-
served. Patients were sub-grouped according to high/
low sTP protein expression using a median cut-off value
[0.072 ng/mg (total protein content), IQR 0.044–0.11].
This cut-off point was used in time-to-event curves. No
association between sTP and tumour response or time-
to-event variables was observed.
Discussion
High levels of TP in tumour tissues and/or serum may
be indicative of poor prognosis, however, it may also
be advantageous in the chemotherapeutic setting when
5-FU-based drugs are used [9,24-26]. In the present
study, we assessed the expression of TP in patients receiv-
ing 5-FU-based chemotherapy as first-line treatment. We
observed that high tTP gene expression was associated
with longer time to progression, but not with tumour
response. These results are in contrast to those observed
in our previous study, which describes the expression of
18 5-FU-related genes in advanced colorectal cancer,
where high tTP expression was associated with shortering the influence of clinicopathological parameters and
Multivariate
* HR 95% CI P*
1
S 1.48 0.94-2.34 NS
S 1.01 0.98-1.04 NS
1
S 1.21 0.74-2.01 NS
1
1.50 0.92-2.42
S 2.12 0.83-4.78 NS
1
0.05 1.61 1.01-2.61 <0.05
1
1.18 0.67-1.98
0.05 7.17 2.60-16.8 <0.05
1
S 1.11 0.59-2.05 NS
ECOG Eastern Cooperative Oncology Group *Statistical method; Cox
oxaliplatin or irinotecan; ‡5-fluorouracil or capecitabine.
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This discrepancy may be due to differences in the cell
types being analysed. In our previous study, tumour tis-
sue was microdissected, whereas the present study used
both stromal and epithelial tumour cells. It is plausible
that tumour stromal cells play an important role in vivo,
during the evolution of primary cancer to metastatic
disease. TP is predominantly expressed in the tumour
stroma by macrophages [9,27] and TAMs play an import-
ant role in the tumour microenvironment [16,28].
Schwartz et al., demonstrated that human colon car-
cinoma cells transfected with TP cDNA exhibited higher
sensitivity to 5-FU compared with parental wild-type
cells, and this phenomenon has also been shown in
other cell lines [29-31]. Furthermore, in a recently pub-
lished study of 76 colorectal cancer patients treated in
the neoadjuvant setting, high tTP expression was asso-
ciated with histopathological response [15]. In contrast,
a study by Yanagisawa et al., observed no association
between tTP gene expression and clinical response in a
cohort of 16 patients analysed in the palliative setting
[32]. However, studies by Kumamoto et al., and Metzger
et al., identified an association between low tTP gene
expression and response when 45 primary colorectal
carcinomas and 38 metastatic lesions were analysed, re-
spectively [13,14]. In the latter three studies, the tissue
samples were microdissected and analysis of TP gene
expression was thus performed predominantly on epi-
thelial tumour cells. Other factors contributing to dis-
crepant results between different studies may be related
to the composition of the patient cohort with regard to
demographic and clinicopathological parameters. For
instance, patients with stable disease were included in
the present, but not in our previous study.
Whether gene and protein expression actually reflect
enzyme activity, is a major question in these studies.
This issue was addressed by Mimori et al., who showed
that TP mRNA detected by in situ reverse-transcriptase
PCR was comparable with TP enzyme activity detected
by high-performance liquid chromatography and enzyme
assays [11]. It is also important to determine whether TP
gene expression in the primary tumour is similar to ex-
pression in the evolved, metastatic lesion. Several studies
indicate a positive correlation between TP expression in
primary tumours and both synchronous and metachro-
nous liver metastases, supporting the use of TP as a
predictive factor for 5-FU-based chemotherapy in the
palliative setting [13,33,34].
In a previous study of stage III colorectal cancer pa-
tients, we observed a positive correlation between tTP
gene expression and numbers of positive lymph nodes,
as well as higher tTP levels in tumours with worse
differentiation grades [25]. In the present study, tTP
expression was high in all stage I patients and in two-thirds of stage II patients. This result implies that pa-
tients with high tTP expression in primary tumours may
have a worse prognosis, regardless of tumour stage.
In the present study, we analysed sTP obtained at the
time of surgery as a possible surrogate marker for TP gene
expression in primary tumours of patients with advanced
CRC. sTP protein expression did not correlate with gene
expression in matched tumour tissue. To evaluate the
potential use of sTP as a predictive factor, measurement
of sTP before and during treatment in a large patient
cohort is therefore necessary.
Conclusions
We demonstrate that high tTP gene expression in non-
microdissected tumour tissue of patients with advanced
colorectal cancer correlates with longer time to progres-
sion, which is related to the effect of treatment. This result
is in contrast to those of previous studies where microdis-
sected epithelial tumour cells have been analysed and may
reflect the presence of stromal cells in the analysed tissue.
The results of the present study suggest that sTP protein
expression is not a useful surrogate marker for TP gene
expression in primary tumour tissue of patients with
advanced CRC.
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